Suppr超能文献

用于制备白细胞去除血小板成分的单采系统的临床试验与局部过程评估

Clinical trial and local process evaluation of an apheresis system for preparation of white cell-reduced platelet components.

作者信息

Adams M R, Dumont L J, McCall M, Heaton W A

机构信息

Blood Centers of the Pacific, Irwin Center, San Francisco, California, USA.

出版信息

Transfusion. 1998 Oct;38(10):966-74. doi: 10.1046/j.1537-2995.1998.381098440862.x.

Abstract

BACKGROUND

A new method for the consistent preparation of white cell (WBC)-reduced plateletpheresis components, the Spectra Leukoreduction System (LRS), was evaluated by clinical trial and local process validation. The centrifuge-based system was projected to decrease the WBC content of plateletpheresis components to a level below 1 x 10(6) per unit. Phase I and II clinical trials were performed. The manufacturer's claims were then tested at the local level with an ongoing quality assurance program.

STUDY DESIGN AND METHODS

In Phase I, a cross-over analysis of five subjects compared LRS to standard plateletpheresis procedures in collection efficiency and component quality: a panel of in vitro measures was taken on Day 0 and Day 5. In Phase II, the LRS process was tested on a larger scale (n = 57; control = 58) with component transfusion. Finally, validation, determination of degree of conformance with standards, and ongoing quality control were performed locally on a newly installed instrument.

RESULTS

Phase I and II trials revealed no significant differences between LRS and control units in donor or recipient safety and comfort, platelet function and yield, or component volume. WBC per-unit values were significantly different: the LRS median per unit was 3.2 x 10(4) WBCs, versus 81.4 x 10(4) for control units. Assessment of process capability gave an estimate of 99-percent confidence that 99.5 percent of LRS units would be WBC reduced to < 1 x 10(6) WBCs. Local process validation and quality control revealed 90-percent confidence that 99 percent of the units would be WBC reduced and 99.9-percent confidence that 75 percent would exceed platelet yield standards; the process was stable over time.

CONCLUSIONS

The LRS is safe for apheresis and the component produced is safe for transfusion with platelet function and yield equivalent to controls and WBC reduction superior to controls. Local process evaluation confirmed that component quality meets the goals of the institution.

摘要

背景

通过临床试验和本地流程验证,对一种用于持续制备白细胞(WBC)减少的单采血小板成分的新方法——Spectra白细胞去除系统(LRS)进行了评估。基于离心机的系统预计可将单采血小板成分中的白细胞含量降低至每单位低于1×10⁶的水平。进行了I期和II期临床试验。随后在本地通过正在进行的质量保证计划对制造商的声明进行了测试。

研究设计与方法

在I期,对5名受试者进行交叉分析,比较LRS与标准单采血小板程序的采集效率和成分质量:在第0天和第5天进行了一组体外测量。在II期,对LRS程序进行了更大规模的测试(n = 57;对照组 = 58),并进行了成分输血。最后,在本地对新安装的仪器进行了验证、确定与标准的符合程度以及持续质量控制。

结果

I期和II期试验显示,LRS与对照单位在供体或受体安全性和舒适度、血小板功能和产量或成分体积方面无显著差异。每单位白细胞值存在显著差异:LRS每单位中位数为3.2×10⁴个白细胞,而对照单位为81.4×10⁴个。过程能力评估得出,有99%的置信度认为99.5%的LRS单位白细胞减少至<1×10⁶个白细胞。本地流程验证和质量控制显示,有90%的置信度认为99%的单位白细胞减少,有99.9%的置信度认为75%的单位将超过血小板产量标准;该过程随时间稳定。

结论

LRS用于血液成分单采是安全的,所生产的成分用于输血是安全的,其血小板功能和产量与对照相当,白细胞减少效果优于对照。本地流程评估证实成分质量符合机构目标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验